All In Biotech

Drug Trial Radar · NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 18, 2019

Primary completion

Feb 27, 2030

Study completion Feb 27, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.

Conditions

  • Advanced Solid Tumor
  • Diffuse Large B Cell Lymphoma
  • Lymphoma, T-Cell
  • Mesothelioma, Malignant
  • Prostatic Neoplasms, Castration-Resistant
  • Endometrial Cancer
  • Ovarian Clear Cell Carcinoma
  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • TulmimetostatDrug

    Tulmimetostat dosed once per day orally in 28 day cycles

  • EnzalutamideDrug

    Enzalutamide dosed once per day orally in 28 day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tulmimetostat Monotherapy Phase 1: Frequency of Dose-limiting toxicities (DLTs)Time frame: DLTs assessed during Cycle 1 (cycle = 28 days)
  2. Tulmimetostat Monotherapy Phase 2: Overall response rate (ORR)Time frame: Up to 30 months
  3. Cohort M8 Part 1: Frequency of Dose-limiting toxicities (DLTs)Time frame: DLTs assessed during Cycle 1 (cycle = 28 days)
  4. Cohort M8 Part 2: Prostate-Specific Antigen 50 (PSA50) ResponseTime frame: Up to 30 months

Locations

80 sites in 7 countries. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida · Withdrawn

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Withdrawn

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland · Withdrawn

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Completed

  • University of Michigan Hospitals

    Ann Arbor, Michigan · Withdrawn

  • South Texas Accelerated Research Therapeutics (START) - Midwest Location

    Grand Rapids, Michigan · Active not recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Completed

  • Roswell Park Cancer Institute

    Buffalo, New York · Withdrawn

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center - NYC

    New York, New York · Withdrawn

  • Weill Medical College of Cornell University

    New York, New York · Withdrawn

  • University of Rochester Medical Center, James P. Wilmot Cancer Center

    Rochester, New York · Withdrawn

  • Montefiore Medical Center, Montefiore Medical Center Laboratories

    The Bronx, New York · Withdrawn

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Withdrawn

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas · Completed

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • CHU Bordeaux Hopital Saint Andre

    Bordeaux, France · Withdrawn

  • CLCC Institut Bergonie

    Bordeaux, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • CHU Nantes Hopital Hotel Dieu

    Nantes, France · Recruiting

  • CHU Nantes Hopital Nord Laennec

    Saint-Herblain, France · Recruiting

  • Hopital Hautepierre

    Strasbourg, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Irccs University Hospital of Bologna

    Bologna, Italy · Completed

  • National Cancer Institute, IRCCS

    Milan, Italy · Recruiting

  • National Cancer Institute, IRCCS

    Milan, Italy · Withdrawn

  • European Institute of Oncology (IEO), IRCCS

    Milan, Italy · Completed

  • European Institute of Oncology (IEO), IRCCS

    Milan, Italy · Recruiting

  • Humanitas San Pio X

    Milan, Italy · Recruiting

  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS

    Roma, Italy · Recruiting

  • Gruppo Humanitas - Humanitas Research Hospital - Cancer Center

    Rozzano, Italy · Recruiting

  • University Teaching Centre, Early Clinical Trials Unit

    Gdansk, Poland · Recruiting

  • Pratia MCM Krakow

    Krakow, Poland · Withdrawn

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.